miR133a regulates cardiomyocyte hypertrophy in diabetes

Diabetes/Metabolism Research and Reviews

Volumn 26, Issue 1, 2010, Pages 40-49

  Feng, Biao ^a   Chen, Shali ^a   George, Biju ^a   Feng, Qingping ^a   Chakrabarti, Subrata ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Cardiomyocytes; Diabetes; Hypertrophy; miRNA

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; MICRORNA; SERUM AND GLUCOCORTICOID REGULATED KINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HEART CONTRACTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; MOUSE; MUTATION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; RNA ANALYSIS; STREPTOZOCIN DIABETES;

ANIMALS; CARDIOMEGALY; CELL CULTURE TECHNIQUES; CELL SURVIVAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; GENE EXPRESSION REGULATION; HEART VENTRICLES; HEMODYNAMICS; MADS DOMAIN PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; MUSCLE CELLS; MYOCYTES, CARDIAC; MYOGENIC REGULATORY FACTORS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 75449100509     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1054     Document Type: Article

References (38)

1. Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond) 2004; 107: 539-557.
2. Liu J. Control of protein synthesis and mRNA degradation by microRNAs. Curr Opin Cell Biol 2008; 20: 214-221.
3. Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatr Res 2007; 61: 24R-29R.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
5. Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006; 38: 228-233.
6. van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006; 103: 18255-18260.
7. Cheng Y, Ji R, Yue J, et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol 2007; 170: 1831-1840.
8. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007; 316: 575-579.
9. Barringhaus KG, Zamore PD. MicroRNAs: regulating a change of heart. Circulation 2009; 119: 2217-2224.
10. Liu N,Williams AH, Kim Y, et al. An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. Proc Natl Acad Sci USA 2007; 104: 20844-20849.
11. Xiao J, Luo X, Lin H, et al. MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. J Biol Chem 2007; 282: 12363-12367.
12. McCarthy JJ, Esser KA. MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J Appl Physiol 2007; 102: 306-313.
13. Liu N, Bezprozvannaya S, Williams AH, et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008; 22: 3242-3254.
14. Ikeda S, Kong SW, Lu J, et al. Altered microRNA expression in human heart disease. Physiol Genomics 2007; 31: 367-373.
15. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007; 100: 416-424.
16. Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007; 13: 613-618.
17. Chen S, Evans T, Mukherjee K, Karmazyn M, Chakrabarti S. Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. J Mol Cell Cardiol 2000; 32: 1621-1629.
18. Evans T, Deng DX, Chen S, Chakrabarti S. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes 2000; 49: 662-666.
19. Farhangkhoee H, Khan ZA, Mukherjee S, et al. Heme oxygenase in diabetes-induced oxidative stress in the heart. J Mol Cell Cardiol 2003; 35: 1439-1448.
20. Hileeto D, Cukiernik M, Mukherjee S, et al. Contributions of endothelin-1 and sodium hydrogen exchanger-1 in the diabetic myocardium. Diabetes Metab Res Rev 2002; 18: 386-394.
21. Peng T, Zhang T, Lu X, Feng Q. JNK1/c-fos inhibits cardiomyocyte TNF-alpha expression via a negative crosstalk with ERK and p38 MAPK in endotoxemia. Cardiovasc Res 2009; 81: 733-741.
22. Feng B, Chen S, Chiu J, George B, Chakrabarti S. Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level. Am J Physiol Endocrinol Metab 2008; 294: E1119-E1126.
23. Chen S, Khan ZA, Karmazyn M, Chakrabarti S. Role of endothelin-1, sodium hydrogen exchanger-1 and mitogen activated protein kinase (MAPK) activation in glucose-induced cardiomyocyte hypertrophy. Diabetes Metab Res Rev 2007; 23: 356-367.
24. Chen S, Khan ZA, Barbin Y, Chakrabarti S. Pro-oxidant role of heme oxygenase in mediating glucose-induced endothelial cell damage. Free Radic Res 2004; 38: 1301-1310.
25. Tu X, Miao L, Kang Y, et al. Effects of dl-praeruptorin A on cultured neonatal rat ventricular cardiomyocytes with hypertrophy induced by endothelin-1. Methods Find Exp Clin Pharmacol 2009; 31: 231-236.
26. Chiu J, Xu BY, Chen S, Feng B, Chakrabarti S. Oxidative stress-induced, poly(ADP-ribose) polymerase-dependent upregulation of ET-1 expression in chronic diabetic complications. Can J Physiol Pharmacol 2008; 86: 365-372.
27. Zeidan A, Javadov S, Chakrabarti S, Karmazyn M. Leptininduced cardiomyocyte hypertrophy involves selective caveolae and RhoA/ROCK-dependent p38 MAPK translocation to nuclei. Cardiovasc Res 2008; 77: 64-72.
28. Karmazyn M, Purdham DM, Rajapurohitam V, Zeidan A. Leptin as a cardiac hypertrophic factor: a potential target for therapeutics. Trends Cardiovasc Med 2007; 17: 206-211.
29. Zeidan A, Javadov S, Karmazyn M. Essential role of Rho/ROCK-dependent processes and actin dynamics in mediating leptin-induced hypertrophy in rat neonatal ventricular myocytes. Cardiovasc Res 2006; 72: 101-111.
30. Khan ZA, Barbin YP, Farhangkhoee H, Beier N, Scholz W, Chakrabarti S. Glucose-induced serum- and glucocorticoid-regulated kinase activation in oncofetal fibronectin expression. Biochem Biophys Res Commun 2005; 329: 275-280.
31. Kuang HY, Zou W, Zhang GB, Gao XY, Yin HQ. The relationship of blood glucose and the expression of insulin-like growth factor-1 receptor mRNA in diabetic cardiomyopathy: a preliminary study with rats Zhonghua Yi Xue Za Zhi. 2007; 87: 1249-1251.
32. Aoyama T, Matsui T, Novikov M, Park J, Hemmings B, Rosenzweig A. Serum and glucocorticoid-responsive kinase-1 regulates cardiomyocyte survival and hypertrophic response Circulation 2005; 111: 1652-1659.
33. Saad S, Stevens VA, Wassef L, et al. High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule. Kidney Int 2005; 68: 985-997.
34. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006; 66: 1277-1281.
35. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9: 435-443.
36. van Rooij E, Liu N, Olson EN. MicroRNAs flex their muscles. Trends Genet 2008; 24: 159-166.
37. Oka T, Komuro I. Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure. Circ J 2008; 72(Suppl. A): A13-A16.
38. Mora S, Pessin JE. The MEF2A isoform is required for striated muscle-specific expression of the insulin-responsive GLUT4 glucose transporter. J Biol Chem 2000; 275: 16323-16328.